Company: CMND
Filing Date: 2025-06-12
Form Type: POS AM
Source: 0001213900-25-053898
Chunk: 17

Company: Clearmind Medicine Inc.
Filing Date: 2025-06-12
Form: POS AM
Chunk 17
---
 such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,”
“continue,” “could,” “due,” “estimate,” “expect,” “goal,” “intend,”
“may,” “objective,” “plan,” “predict,” “potential,” “positioned,”
“seek,” “should,” “target,” “will,” “would,” and other similar expressions
that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology.
These forward-looking statements include, but are not limited to, statements about:

| ● | the                                                                                           
 ability of our pre-clinical and any future clinical trials to demonstrate safety and efficacy 
 of our future product candidates, and other positive results;                                 |

| ● | the                                                                                       
 timing and focus of our future preclinical studies and clinical trials, and the reporting 
 of data from those studies and trials;                                                    |

| ● | the size of the market opportunity                                                                                                  
 for our future product candidates, including our estimates of the number of patients who suffer from the diseases we are targeting; |

| ● | the success of competing therapies that are or may 
 become available;                                  |

| ● | the beneficial characteristics, safety, efficacy and                                                                               
 therapeutic effects of our future product candidates, as well as the potential healthcare costs saved through utilizing our future 
 product candidates;                                                                                                                |

| ● | the ability of our future product candidates to address    
 needs not currently addressed by the psychedelic industry; |

| ● | the ability of our future product candidates to address    
 needs not currently addressed by the psychedelic industry; |

| ● | our ability to obtain and maintain regulatory approval 
 of our future product candidates;                      |

| ● | our plans relating to the further development of our                                         
 future product candidates, including additional disease states or indications we may pursue; |

| ● | existing regulations and regulatory developments in 
 the United States and other jurisdictions;          |

| ● | our plans and ability to obtain or protect intellectual                                                                             
 property rights, including extensions of patent terms where available and our ability to avoid infringing the intellectual property 
 rights of others;                                                                                                                   |

| ● | the ability of our management team to oversee our drug 
 research programs;                                     |

| ● | the need to hire additional personnel and our ability 
 to attract and retain such personnel;                 |

| ● | our estimates regarding expenses, future revenue, capital 
 requirements and needs for additional financing;          |

| ● | our dependence on